TANGRAM
Live / Applied — Suspended — suspension check completed, case still suspended (as of 10 Sept 2026)
What this means for you
Not registered yet, but its 18 Jun 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99240392
- Mark type
- Word mark
- Filed
- 18 Jun 2025
- Attorney of record
- Anna King
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation.
- Class 009 — Scientific and electric apparatus: Downloadable and recorded computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; recorded and downloadable artificial intelligence and machine learning software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable databases in the fields of pharmaceuticals, medicines and drug discovery; electronic databases for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery
- Class 040 — Treatment of materials: Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.
- Class 042 — Scientific and technological services: Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; pharmaceutical research and development services; drug discovery services; human genetic research; scientific and technical data analysis in the fields of pharmaceuticals, medicines and drug discovery, namely, analysis of pharmaceutical and medical data; design, development, creation and maintenance of computer software platforms and computer software for use in the fields of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; design and development of computer-simulated models; Software as a Service (SaaS) services featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the fields of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and generating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the fields of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.
Owner
- TANGRAM THERAPEUTICS PLC, LONDON, GB
- E-THERAPEUTICS PLC, LONDON, GB
Prosecution history
- 10 Sept 2026 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 10 Jun 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 13 Mar 2026 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 13 Mar 2026 — LETTER OF SUSPENSION E-MAILED
- 13 Mar 2026 — SUSPENSION LETTER WRITTEN
- 11 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 11 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 12 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 12 Nov 2025 — NON-FINAL ACTION E-MAILED
- 12 Nov 2025 — NON-FINAL ACTION WRITTEN
- 06 Nov 2025 — ASSIGNED TO EXAMINER
- 24 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 18 Jun 2025 — NEW APPLICATION ENTERED
- 18 Jun 2025 — APPLICATION FILING RECEIPT MAILED